Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Loss of inhibitor of kappa B epsilon was found to drive NF-κB pathway activity and migration and proliferation of CLL cells.
CAR T-cell therapies effectively treated patients with Richter transformation, an aggressive subtype of CLL.
Patients with Richter transformation had improved outcomes when treated with venetoclax-based treatment regimens.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Paolo Ghia, MD, PhD talks about his session on monoclonal B-cell lymphocytosis presented at the AACR Annual Meeting 2024.
Elias Jabbour, MD, discusses the latest news and novel therapies in CLL.
Advertisement
In patients with CLL, zanubrutinib showed advantages in PFS and CR rates with "potentially improved" OS.
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
Treatment with ibrutinib plus FCR followed by ibrutinib maintenance induced durable and deep responses in patients with CLL.
The CAR-T therapy was approved based on response rate and duration of response data from the TRANSCEND CLL 004 trial.
The researchers developed CAR T-cells that target and eliminate mutated CLL cells while sparing healthy B-cells.
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
NX-2127, a first-in-class therapy, induced BTK degradation and clinical responses in CLL resistant to BTK inhibitors.
MRD-directed ibrutinib plus venetoclax therapy improved PFS in patients with CLL.
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
The presence of two or more mutations are associated with high-risk cell features.
Chaitra Ujjani, MD, discusses research on the incidence and management of COVID-19 infections in patients with CLL.
Some mutations are associated with shorter event-free survival in low-risk, early-stage CLL.
The updated analysis found that combining rituximab with ibrutinib did not provide additional treatment benefit.
The therapy is currently under investigation in multiple clinical trials.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.